Long-COVID: Ultrasensitive multiplex protein biomarker profiling reveals subclinical neuroinflammatory and innate immune dysregulation without correlation to symptom severity
🚨LongC0VID patients show a hidden cytokine-storm + neuroinflammation signature that only ULTRA-SENSITIVE PROTEOMICS can detect. Yet the biology doesn’t match how sick they feel. The real driver may be central sensitisation or brain rewiring.🤔
➡️Very interesting small Norwegian study, bear with me!
- Routine labs are normal in longC0VID, yet patients have persistent fatigue, cognitive issues, depression, and other symptoms more than a year after infection.
- In this matched case-control study (48 longC0VID patients vs 48 fully recovered controls, median ~65–72 weeks post-infection), ultrasensitive NULISAseq proteomics (123 CNS/immune biomarkers at attomolar sensitivity) detected clear biological differences invisible to standard tests.
- 19 proteins were significantly dysregulated; top upregulated markers included CCL22, IL-6R and CST3. Pathway analysis showed activated Pathogen-Induced Cytokine Storm, Neuroinflammation, and IL-10 signalling pathways, pointing to low-grade innate immune activation and neuroinflammatory signals.
- Hierarchical clustering split longC0VID patients into two biological subgroups (one dominated by metabolic reprogramming/mitochondrial dysfunction and cytokine-storm features, the other by neuroinflammation and related signalling).
- Critically, neither the protein levels nor the biological clusters correlated with symptom severity, fatigue, depression, cognitive scores, or any patient-reported outcomes. Conventional PCA also showed no clear patient-control separation.
- The study does not examine reinfection or vaccination status. It simply compares people with ongoing longC0VID symptoms versus people who fully recovered, both more than one year after documented SARSCoV2 infection.
➡️The authors conclude that subclinical immune/neuroinflammatory dysregulation is present but does not map directly onto how sick patients feel, implying additional mechanisms (central sensitisation, epigenetic changes or similar) convert peripheral signals into the clinical picture.
‼️So, according to these authors, LongC0VID harbours a real but hidden biological footprint of innate immune activation and neuroinflammation that standard medicine cannot see and that does not match the intensity of patients’ symptoms, pointing to brain-level amplification mechanisms as the missing link.
‼️Important take-away:
1. For the millions still living with longC0VID, this matters because it shows why ordinary blood tests are repeatedly “normal” while people remain disabled. It validates that low-level immune and neuroinflammatory changes can persist >1 year and explains the frustrating mismatch between lab results and lived experience. Clinically it argues against relying solely on symptom scores or standard inflammatory markers for diagnosis or trial endpoints, and it supports research into treatments that address both residual immune signalling and central sensitisation/pain-processing pathways. It also reinforces that longC0VID is heterogeneous at the molecular level even when symptoms look similar.
2. Finally, this study doesn’t contradict earlier ultrasensitive findings, actually, it confirms and extends them. The attomolar view of longC0VID as a state of low-grade, heterogeneous innate immune and neuroinflammatory dysregulation that is largely invisible to routine labs and poorly linked to symptom intensity is holding up across platforms and other cohorts.
We’re getting somewhere!
#AvoidSars2 #AvoidReinfection
nature.com/articles/s4159…View quoted post on X
